Aakaar Medical TechnologiesShare price, financial results, shareholding and management
- Market cap
- ₹94 cr
- Stock P/E
- 14.1peers 44.2
- Book value
- ₹38.5
- Price to book
- 1.71
- EV / operating profit
- 9.3
- Market cap to sales
- 1.40
- ROCE · FY26
- 18.5%
- ROE · FY26
- 17.1%
- ROE, 3-year average
- 25.6%
- Operating margin · FY26
- 15.4%peers 14.0%
- Sales growth, 3 years
- 26.9%
- Profit growth, 3 years
- 45.6%
- Debt to equity
- 0.34peers 0.14
- Borrowings
- ₹18.5 cr
- Interest cover
- 6.1×
- Cash from business / op. profit
- -81%
- Debtor days
- 203
- Pledged
- 0.00%
- Promoter holding
- 67.05%
- Change in promoter holding
- +0.04 pts
- Shareholders
- 550
- 52-week high / low
- ₹85 / ₹46
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Aakaar Medical Technologies share price chart
Close on 17 Nov 2026 · +0.61% on the day · Vol 6,400
Daily prices to 17 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 17 Nov 2026
- 1 month
- -7.0%
- 3 months
- +24.4%
- 6 months
- +9.9%
- 1 year
- -14.9%
- Since IPO
- -8.3%
- Traded a day, 20 days
- ₹0.07 cr
- Taken for delivery
- 95%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +9% | +10% |
| 3 years, a year | +27% | +46% |
| Latest half, H2 FY26 | +23% | +33% |
About Aakaar Medical Technologies: business, products and customers
Aakaar Medical Technologies sells skin and hair care products, injectables and aesthetic devices to dermatologists and skin clinics across India, partly under its own brands and partly as the Indian seller of foreign brands. Its shares trade on NSE Emerge.
Aakaar, based in Mumbai, sells only to doctors: dermatologists, plastic surgeons and aesthetic clinics, who use the products in treatments or pass them on to patients. It carries about 150 products from brands in Korea, Spain, Italy, Austria and the USA, such as the fillers of Croma and the botulinum toxin Letybo, alongside its own brands like the DRS1512 hair range, which contract manufacturers make to its formulas. It owns no factory.
Own brands earn a much higher gross margin than imported ones, so the mix between them moves profit. Doctors have long been sold on credit, through a consignee agent, Parekh Integrated Services, that stores the goods, bills the doctors and collects; so money owed by customers is large, and the company has started moving to local stockists who pay within weeks. Conferences and workshops are held early in the year and sales are heavier later, so the first half earns little and the second half carries the year.
Read more about the business
The offer document says no listed company in India or abroad has a comparable business. Its industry section names Allergan, Alma and Galderma among the foreign brands in Indian aesthetics, and Skinnovation, Kaya and Dr. Reddy's Laboratories among the domestic ones. In FY26 the company launched Letybo, exosome ranges from Italy and Korea and a DermLite device, and started Xelix, a network of partner clinics.
From the red herring prospectus (June 2025), the FY26 annual report, the investor presentation of June 2026 and the earnings call transcripts of November 2025 and May 2026.
Read the deeper study ↓In its favour
- Sales have grown fast: 27% a year over three years.
- The promoters own a large part of the company: 67.05%.
To watch
- The move to stockists for more than 90% of sales from April 2026 and whether debtor days fall towards the 100 to 110 management talks of.
- Sales growth in FY27 against the 30% or more the chief executive aims for, and whether the first half improves on FY26.
- Use of the ₹11.0 cr of working capital money and ₹3.3 cr for general purposes still unspent from the IPO at March 2026.
- Recovery of the ₹0.40 cr deposit flagged by the auditor, and the Xelix clinic count against the 50 targeted.
- Customers take longer to pay than before: 203 days in FY26, against 118 in FY20.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Aakaar Medical Technologies revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew roughly in step with sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.
Aakaar Medical Technologies half-yearly results
SME companies report every six months · ₹ crore
| H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|
| Sales | 33.88 | 25.32 | 41.64 |
| Expenses | 25.53 | 25.56 | 31.22 |
| Operating profit | 8.35 | -0.23 | 10.41 |
| OPM | 24.6% | -0.9% | 25.0% |
| Interest | 0.91 | 1.04 | 0.76 |
| Depreciation | 0.07 | 0.05 | 0.08 |
| Profit before tax | 7.48 | -1.02 | 10.22 |
| Net profit | 5.57 | -0.78 | 7.42 |
Aakaar Medical Technologies profit and loss
Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Sales | 22.89 | 12.44 | 19.47 | 32.78 | 46.11 | 61.58 | 66.96 |
| Expenses | 20.01 | 11.54 | 17.07 | 29.25 | 41.11 | 51.81 | 56.65 |
| Operating profit | 2.88 | 0.90 | 2.40 | 3.53 | 5 | 9.77 | 10.31 |
| OPM | 12.6% | 7.2% | 12.3% | 10.8% | 10.8% | 15.9% | 15.4% |
| Other income | 0.12 | 0.12 | 0.04 | 0.09 | 0.16 | 0.18 | 0.80 |
| Interest | 0.46 | 0.23 | 0.21 | 0.43 | 1.14 | 1.71 | 1.80 |
| Depreciation | 0.04 | 0.03 | 0.02 | 0.09 | 0.14 | 0.12 | 0.13 |
| Profit before tax | 2.50 | 0.76 | 2.21 | 3.10 | 3.88 | 8.12 | 9.19 |
| Tax rate | 26.8% | 28.9% | 26.7% | 30.6% | 26.0% | 25.7% | 27.7% |
| Net profit | 1.83 | 0.54 | 1.62 | 2.15 | 2.87 | 6.03 | 6.64 |
| EPS ₹ | 183 | 54 | 23.14 | 30.71 | 41 | 5.79 | 4.99 |
| Dividend payout | 0.0% | 0.0% | 34.6% | 24.4% | 0.0% | 0.0% | 0.0% |
Aakaar Medical Technologies profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Operating margin | 12.6% | 7.2% | 12.3% | 10.8% | 10.8% | 15.9% | 15.4% |
| Tax rate | 26.8% | 28.9% | 26.7% | 30.6% | 26.0% | 25.7% | 27.7% |
| ROCE | · | 8.2% | 20.9% | 25.8% | 23.3% | 26.7% | 18.5% |
| ROE | · | 7.6% | 21.0% | 24.3% | 25.9% | 33.7% | 17.1% |
| Dividend payout | 0.0% | 0.0% | 34.6% | 24.4% | 0.0% | 0.0% | 0.0% |
Aakaar Medical Technologies debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business used more cash than it brought in. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Aakaar Medical Technologies balance sheet
At each 31 March · ₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Equity capital | 0.10 | 0.10 | 0.70 | 0.70 | 0.70 | 10.42 | 14.17 |
| Reserves | 6.75 | 7.30 | 7.33 | 8.96 | 11.84 | 12.84 | 40.38 |
| Net worth | 6.85 | 7.40 | 8.03 | 9.66 | 12.54 | 23.26 | 54.55 |
| Borrowings | 5.88 | 3.88 | 3.82 | 5.87 | 15.05 | 22.74 | 18.53 |
| Other liabilities | 3.56 | 3.03 | 6.15 | 7.70 | 6.42 | 8.16 | 6.34 |
| Total liabilities | 16.29 | 14.31 | 18 | 23.23 | 34.01 | 54.16 | 79.42 |
| Fixed assets | 0.06 | 0.04 | 0.20 | 0.36 | 0.28 | 0.24 | 0.29 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0.40 |
| Investments | 0.47 | 0.11 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 15.76 | 14.16 | 17.80 | 22.87 | 33.73 | 53.92 | 78.73 |
| Receivables | · | · | · | · | · | · | 37.23 |
| Inventory | · | · | · | · | · | · | 19.75 |
| Cash | · | · | · | · | · | · | 16.24 |
| Trade payables | · | · | · | · | · | · | 1.88 |
Aakaar Medical Technologies cash flow
₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | -0.38 | 4.31 | 0.48 | -2.93 | -8.04 | -5.41 | -8.36 |
| Cash from investing | 0.10 | 0.37 | -0.23 | -0.32 | -0.04 | -0.05 | 0.05 |
| Cash from financing | 0.28 | -2 | -0.81 | 1.17 | 8.19 | 10.71 | 18.80 |
| Net cash flow | 0 | 2.68 | -0.56 | -2.08 | 0.11 | 5.25 | 10.49 |
| Capital spending | · | · | · | · | · | · | 0.58 |
Working capital
Days
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 118 | 136 | 104 | 114 | 129 | 166 | 203 |
| Inventory days | 234 | 366 | 282 | 274 | 247 | 202 | 256 |
| Days payable | 28 | 99 | 65 | 62 | 32 | 49 | 24 |
| Cash conversion cycle | 324 | 403 | 321 | 326 | 344 | 320 | 434 |
| Working capital days | 189 | 238 | 105 | 102 | 94 | 97 | 199 |
Aakaar Medical Technologies peers and competitors
Listed SME companies in the same industryBy sales, Aakaar Medical Technologies is number 5 of the 8 listed SME companies in personal products.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Anondita Medicare | 1,903 | 56.0 | 137 | 34 | 37.0% | 0.26 |
| H. R. Hygiene Products | 139 | 12.6 | 130 | 11 | 14.0% | 0.51 |
| Recode Studios | 486 | 44.2 | 80 | 11 | 21.0% | 0.30 |
| Medistep Healthcare | 29 | 4.9 | 70.8 | 6 | 11.6% | 0.14 |
| Aakaar Medical Technologies | 94 | 14.1 | 67 | 6.6 | 15.4% | 0.34 |
| Macobs Technologies | 195 | 67.2 | 41.4 | 2.9 | 8.3% | 0.06 |
| Ravelcare | 68 | 13.1 | 27 | 5.2 | 26.2% | 0.00 |
| Novateor Research Laboratories | 23 | 227.0 | 3.8 | 0.1 | -2.6% | 0.09 |
| Median of the 7 others | 139 | 44.2 | 70.8 | 6 | 14.0% | 0.14 |
Aakaar Medical Technologies shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Foreign and Indian funds own a noticeable share. The number of shareholders has come down.
Aakaar Medical Technologies shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Jun 25 | Sep 25 | Mar 26 | |
|---|---|---|---|
| Promoters | 67.01% | 67.01% | 67.05% |
| Foreign investors (FIIs) | 1.87% | 0.50% | - |
| Indian institutions (DIIs) | 12.33% | 10.73% | 11.17% |
| HNIs (over ₹2 lakh each) | 5.33% | 7.31% | 6.60% |
| Small holders (up to ₹2 lakh) | 11.26% | 9.16% | 9.39% |
| Companies and others | 2.20% | 5.29% | 5.79% |
| Number of shareholders | 920 | 603 | 550 |
The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.
Aakaar Medical Technologies study: the business from its own documents
Read from 7 of the company's own documentsAakaar Medical Technologies so far
From the company's own record
- June 2013Company formed
- 27 June 2025Listed on NSE Emerge at ₹72
- 31 March 2026Promoters at 67.05%
- 21 July 2025Highest close since listing, ₹87.83
Aakaar Medical Technologies key facts from the filings
Each figure with the document it comes from
- Own brands
- 37%
- Share of FY26 revenue from the company's own brands, which helped gross margin rise from 54% to 59%.Earnings call transcript, May 2026, p.4
- Doctors served
- 6,300+
- Doctors and clinics billed in FY26, up from about 5,200 a year earlier.Investor presentation, June 2026, p.7; Earnings call transcript, May 2026, p.4
- Top ten customers
- 8.16%
- Share of FY25 revenue from the ten largest buyers; no single doctor matters much.Red herring prospectus, p.146
- Top ten suppliers
- 84.89%
- Share of FY25 cost of goods from ten suppliers, the largest at 16.39%.Red herring prospectus, p.141
- Sales through one agent
- 80.88%
- Share of FY25 revenue billed through the consignee agent Parekh Integrated Services, which also collects the dues.Red herring prospectus, p.33
Show 5 more facts
- First half against second
- 38% / 62%
- Split of FY26 sales between the halves; the first half lost ₹0.78 cr and the second earned ₹7.4 cr.Earnings call transcript, May 2026, p.4 and p.5
- Money owed by doctors
- ₹37.2 cr
- Trade receivables at March 2026, up from ₹28.0 cr, on FY26 sales of ₹67.0 cr.Annual report FY26, p.50
- Cash from operations
- ₹-8.4 cr
- FY26 operating cash flow, after ₹-5.4 cr in FY25, as receivables and stock grew.Annual report FY26, p.52
- IPO money unspent
- ₹14.3 cr
- Held in a fixed deposit at March 2026, mostly the working capital share due to be used in FY27.Annual report FY26, p.60; Earnings call transcript, May 2026, p.12
- Auditor's emphasis
- ₹0.40 cr deposit
- Placed with Accredited Consultants for a bank guarantee in that firm's legal case; recovery depends on the outcome.Annual report FY26, p.41
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
At the May 2026 call the chief executive said the company aims to keep growing at 30% a year or more, expects FY27 growth to be better than FY26 and the first half to be better than last year's, and hopes to move to the main board within about three years. The company is shifting to stockists for more than 90% of sales from April 2026 with payment due in 40 to 45 days, aims to bring debtor days down to about 100 to 110, and expects at least 50 Xelix partner clinics by the end of the year, from 16.
| What management said | When | What happened |
|---|---|---|
| Sales growth of 25% to 30% in FY26 | November 2025 call | Sales up 8.7%, to ₹67.0 cr |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Aakaar earns a trading margin on foreign aesthetic brands and a richer one on its own products, sold to thousands of skin doctors.
Its weak spots are long credit to doctors, cash tied in stock and receivables, dependence on a few foreign suppliers, and a year whose profit comes almost all in the second half.
AverageCan it set its own prices?On its own brands, yes to a fair degree; on imported brands the margin is set with the foreign owner and competes with global companies.
AverageHow strong is it against rivals?It has a wide range and long ties with doctors, but competes with large global and Indian companies, and its imported brands can change hands.
StrongWho are its customers?Thousands of doctors and clinics, none of them large, so losing one barely matters.
WatchDoes it need a lot of money?Not for plants, but a lot for credit to doctors and stock, and operating cash has been negative for years.
StrongCan it keep finding new work?Yes so far. It adds doctors and new products each year and has a pipeline of approvals for imported products.
WatchDo good and bad years swing a lot?Within each year, yes: the first half carries the event costs and the second half most of the sales and profit. Across years it has stayed profitable, but growth slowed sharply in FY26.
Who runs Aakaar Medical Technologies?
Promoters, directors and officers; tap a name for the background
DRDilip Ramesh MeswaniPromoter and Managing Director · holds 48.20%
Bachelor of Science from the University of Bombay and a post diploma in Medical Electronics from Shri Bhagubhai Mafatlal Polytechnic, with over 24 years in medical aesthetics; began in aesthetics in 1999 through a proprietary business selling aesthetic devices, sole proprietor of Coherent Medical Systems since 1998, and a director since the company was formed in 2013. Managing Director for five years from July 2024.
Red herring prospectus, p.129, p.171 and p.173BDBindi Dilip MeswaniPromoter, Chairperson and Non-Executive Director · holds 12.84%
Master of Commerce from Maharaja Sayajirao University of Baroda, with over 10 years in medical aesthetics; a director since 2013 and also a director of Revigen Medicare. The offer document states that Dilip Ramesh Meswani and Bindi Dilip Meswani are husband and wife.
Red herring prospectus, p.173 and p.174RBRahul Babasaheb SawakhandeChief Executive Officer and Executive Director · holds 4.10%
Bachelor of Medicine and Surgery from Maharashtra University of Health Sciences, Nashik, and a diploma in business management; over 15 years in dermatology and medical regulatory affairs at Piramal Healthcare, Abbott Healthcare, Pfizer and Galderma India before joining as head of business in December 2015.
Red herring prospectus, p.173RPRakesh Pramod ParekhChief Financial Officer
Appointed Chief Financial Officer from 12 December 2025, after Sweta Shah resigned from the post.
Annual report FY26, p.22DPDeepanjan PeriwalIndependent Director
Chartered Accountant and Bachelor of Commerce from Nagpur University, with a senior management programme from IIM Ahmedabad and registration as a valuer; earlier with Ernst & Young and now with City First Financial Advisors; over 15 years in accounts and finance. On the board since December 2024.
Red herring prospectus, p.173RIRajendra Indubhai DhandhukiaIndependent Director
Bachelor of Science from the University of Bombay and a diploma in marketing and sales management from Bhartiya Vidya Bhavan, with over 15 years in the pharmaceutical industry, earlier at Abbott India. On the board since December 2024.
Red herring prospectus, p.174Aakaar Medical Technologies latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹41.6 cr (+23%), net profit ₹7.4 cr (+33%) on H2 FY25.
- Shareholding, 31 March 2026: promoters 67.01% to 67.05%; Aarth AIF Growth Fund up to 3.61%.
Aakaar Medical Technologies announcements
27 on record, latest first; each opens the filing on the exchange
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Analysts/Institutional Investor Meet/Con. Call UpdatesOutcome of the MeetPDF ↗
- Analysts/Institutional Investor Meet/Con. Call UpdatesSchedule of meetPDF ↗
- Analysts/Institutional Investor Meet/Con. Call UpdatesOutcomePDF ↗
- Analysts/Institutional Investor Meet/Con. Call UpdatesSchedule of meetPDF ↗
- Analysts/Institutional Investor Meet/Con. Call UpdatesCancellation Of Investors Meet which was scheduled to be held on 21.08.26PDF ↗
- Analysts/Institutional Investor Meet/Con. Call UpdatesSchedule of meetPDF ↗
- General UpdatesGeneral UpdatesPDF ↗
- Updates'Board Comments on Notice dated 14.07.2026 from National Stock Exchange'PDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
Aakaar Medical Technologies annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
- 31 May 2026 ↗read
- 30 Nov 2025 ↗read
Aakaar Medical Technologies share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Aakaar Medical Technologies' data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,41,72,816 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- !Earnings per share changes basis between FY21 (₹54.00) and FY22 (₹23.14) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY20 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Aakaar Medical Technologies
What does Aakaar Medical Technologies do?
Aakaar Medical Technologies sells skin and hair care products, injectables and aesthetic devices to dermatologists and skin clinics across India, partly under its own brands and partly as the Indian seller of foreign brands. Its shares trade on NSE Emerge.
What is the share price of Aakaar Medical Technologies?
₹66 at the close on 17 Nov 2026, from the exchange's daily figures.
What is the market cap of Aakaar Medical Technologies?
₹94 cr at the close on 17 Nov 2026, on 1,41,72,816 shares.
What is the P/E of Aakaar Medical Technologies?
14.1 times FY26 profit at the close on 17 Nov 2026 (our arithmetic).
What are Aakaar Medical Technologies' revenue and profit?
Revenue ₹67 cr and profit after tax ₹7 cr in FY26.
Who are the promoters of Aakaar Medical Technologies?
Dilip Ramesh Meswani, Bindi Dilip Meswani; promoters held 67.05% at 31 March 2026.
What was the IPO price of Aakaar Medical Technologies?
₹72 a share; it listed on 27 June 2025.
What is Aakaar Medical Technologies' website?
aakaarmedical.in
More SME companies like Aakaar Medical Technologies
Other listed SME companies in personal products, the closest in size first, each read from its own documents.
- RavelcareRAVEL · BSE SME · Personal ProductsMarket cap ₹64 cr
- H. R. Hygiene ProductsHRHYGIENE · BSE SME · Personal ProductsMarket cap ₹150 cr
- Macobs TechnologiesMACOBSTECH · NSE Emerge · Personal Products · listed 2024Market cap ₹186 cr
- Medistep HealthcareMEDISTEP · NSE Emerge · Personal Products · listed 2025Market cap ₹27 cr
- Recode StudiosRECODE · BSE SME · Personal ProductsMarket cap ₹373 cr
- Novateor Research LaboratoriesNOVATEOR · BSE SME · Personal ProductsMarket cap ₹17 cr
Every listed SME company in Personal Products → · SME companies listed in 2025 →
Built from 2 earnings call transcripts, 2 investor presentations, 2 annual reports, 1 offer document, 27 exchange announcements, 3 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.